{"pub": "reuters", "url": "https://ca.reuters.com/article/businessNews/idCAKBN1WU1EB-OCABS", "downloaded_at": "2019-10-15 11:25:19.622210+00:00", "title": "Johnson & Johnson posts 23% rise in third-quarter profit", "language": "en", "text": "FILE PHOTO: The company logo for Johnson & Johnson is displayed on a screen to celebrate the 75th anniversary of the company's listing at the New York Stock Exchange (NYSE) in New York, U.S., September 17, 2019. REUTERS/Brendan McDermid/File Photo\n\n(Reuters) - Johnson & Johnson (JNJ.N) on Tuesday posted a 22.9% rise in third-quarter profit, boosted by demand for its cancer drugs Darzalex and Imbruvica.\n\nNet earnings rose to $4.83 billion, or $1.81 per share, in the quarter, from $3.93 billion, or $1.44 per share, a year earlier.", "description": "Johnson & Johnson on Tuesday posted a 22.9% rise in third-quarter profit, boosted by demand for its cancer drugs Darzalex and Imbruvica.", "authors": ["Reuters Editorial", "Min Read"], "top_image": "https://s4.reutersmedia.net/resources/r/?m=02&d=20191015&t=2&i=1441072546&w=1200&r=LYNXMPEF9E0S9-OCABS", "published_at": "2019-10-15"}